[
  {
    "ts": null,
    "headline": "Why The Narrative Around West Pharmaceutical Services (WST) Is Shifting After New Valuation Updates",
    "summary": "West Pharmaceutical Services has seen its fair value estimate trimmed slightly, with the price target moving from about US$345.71 to US$338.57 per share as analysts refresh their models around growth and risk. The latest commentary links this shift to somewhat softer revenue growth assumptions and a marginally higher discount rate, which together pull the valuation estimate a bit lower, even as the core story remains under debate. Stay tuned to see how you can keep on top of these evolving...",
    "url": "https://finnhub.io/api/news?id=715031b976d87dcb2b1090efc005114e55bfb725cdbb59323e27a21d53f25f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770512734,
      "headline": "Why The Narrative Around West Pharmaceutical Services (WST) Is Shifting After New Valuation Updates",
      "id": 138389860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services has seen its fair value estimate trimmed slightly, with the price target moving from about US$345.71 to US$338.57 per share as analysts refresh their models around growth and risk. The latest commentary links this shift to somewhat softer revenue growth assumptions and a marginally higher discount rate, which together pull the valuation estimate a bit lower, even as the core story remains under debate. Stay tuned to see how you can keep on top of these evolving...",
      "url": "https://finnhub.io/api/news?id=715031b976d87dcb2b1090efc005114e55bfb725cdbb59323e27a21d53f25f38"
    }
  }
]